黄龙止咳颗粒联合丙卡特罗、布地奈德治疗变异性哮喘急性发作期导致的慢性咳嗽的疗效  

The efficacy of Huanglong Zhike granules combined with procaterol and budesonide in the treatment of children with chronic cough caused by acute exacerbation of variant asthma

作　　者：王莉[1] 徐婷 WANG Li;XU Ting(Department of Pharmacy,Xuzhou Central Hospital,Xuzhou,Jiangsu 221000,China)

机构地区：[1]江苏省徐州市中心医院药剂科,江苏徐州221000

出　　处：《检验医学与临床》2024年第24期3621-3625,共5页Laboratory Medicine and Clinic

基　　金：国家自然科学基金项目(81700078)。

摘　　要：目的探讨分析黄龙止咳颗粒联合丙卡特罗、布地奈德对变异性哮喘急性发作期导致的慢性咳嗽患儿的临床疗效,以及对基质金属蛋白酶9(MMP-9)、肿瘤坏死因子-α(TNF-α)水平及嗜酸性粒细胞(EOS)计数的影响。方法选取2019年1月至2022年1月收治的变异性哮喘急性发作期导致的慢性咳嗽患儿60例为研究对象,按照随机数字表法分为治疗A组和治疗B组,每组各30例。治疗A组给予口服丙卡特罗与布地奈德治疗,治疗B组则在治疗A组基础上加用黄龙止咳颗粒治疗。评估两组的疗效、临床症状评分、哮喘控制测试(ACT)评分、圣·乔治呼吸问卷(SGRQ)评分、肺功能、不良反应发生情况,比较两组血清MMP-9、TNF-α水平及EOS计数。结果治疗B组中医、西医临床总有效率分别为93.3%、90.0%,明显高于治疗A组的53.3%、63.3%,差异均有统计学意义(χ^(2)=12.273、10.752,P<0.05)。干预后,两组患儿的临床症状评分、ACT评分与SGRQ评分均有明显改善,与干预前比较,差异均有统计学意义(P<0.05);干预后,治疗B组的临床症状评分、ACT评分与SGRQ评分均明显优于治疗A组,差异均有统计学意义(P<0.05)。与干预前比较,干预后两组的第1秒用力呼气容积(FEV1)、用力肺活量(FVC)、呼气峰值流速(PEF)均明显升高,差异均有统计学意义(P<0.05);干预后,治疗B组患儿的肺功能指标明显优于治疗A组,差异均有统计学意义(P<0.05)。干预后,两组血清MMP-9、TNF-α水平及EOS计数均明显降低,与干预前比较,差异均有统计学意义(P<0.05);干预后,治疗B组的MMP-9、TNF-α水平及EOS计数均明显低于治疗A组,差异均有统计学意义(P<0.05)。治疗A组与治疗B组不良反应总发生率比较,差异无统计学意义(χ^(2)=1.176,P=0.278)。结论黄龙止咳颗粒联合丙卡特罗与布地奈德治疗变异性哮喘急性发作期导致的慢性咳嗽患儿临床疗效更为显著,可改善患儿的临床症状与肺功能,控制Objective To explore and analyze the clinical efficacy of Huanglong Zhike granules combined with procaterol and budesonide in children with chronic cough caused by acute exacerbation of variant asthma,as well as their effects on the levels of matrix metalloproteinase-9(MMP-9),tumor necrosis factor-α(TNF-α)and eosinophils(EOS)count.Methods A total of 60 children with chronic cough caused by acute exacerbation of variant asthma admitted from January 2019 to January 2022 were selected as the study subjects.They were randomly divided into treatment group A and treatment group B using random number table method,with 30 cases in each group.Treatment group A was treated with procaterol and budesonide,while treatment group B was treated with Huanglong Zhike granules in addition to treatment group A.Evaluated the efficacy,clinical symptom score,asthma control test(ACT)score,St.George′s Respiratory Questionnaire(SGRQ)score and incidence of adverse reactions,detected the serum MMP-9,TNF-αlevels and EOS count,lung function of the two groups.Results The clinical effective rates of traditional Chinese and Western medicine in treatment group B were 93.3%and 90.0%respectively,which were significantly higher than those in treatment group A(53.3%and 63.3%)respectively,the differences were statistically significant(χ^(2)=12.273,10.752,P<0.05).After intervention,the clinical symptom scores,ACT scores and SGRQ scores of both groups of children improved significantly,the differences were statistically significant compared with before intervention(P<0.05).After intervention,the clinical symptom score,ACT score and SGRQ score of treatment group B were significantly better than those of treatment group A,the differences were statistically significant(P<0.05).Compared with before intervention,the forced expiratory volume in one second(FEV 1),forced vital capacity(FVC)and peak expiratory flow rate(PEF)of both groups increased significantly after intervention,the differences were statistically significant(P<0.05).After intervention,th

关 键 词：黄龙止咳颗粒 丙卡特罗 布地奈德 变异性哮喘 慢性咳嗽 急性发作期 

分 类 号：R725.6[医药卫生—儿科]